A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Overview and Mission Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. Our Business Strategy Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care. We believe that engaging with providers and patients throughout their consumer and patient journey will better enable us to execute our strategies and fulfill our mission.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 825M | 825M | 838M | 753M | 678M | 691M |
| Net Income | -366M | -366M | -127M | -263M | -112M | -27M |
| EPS | $-3.95 | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
| Free Cash Flow | -10M | -10M | -19M | -121M | -152M | 600K |
| ROIC | -71.4% | -59.6% | -16.3% | -30.8% | -12.1% | -2.6% |
| Gross Margin | 69.9% | 69.9% | 69.9% | 68.6% | 70.2% | 78.6% |
| Debt/Equity | 0.57 | 0.57 | 0.20 | 0.19 | 0.16 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -387M | -387M | -124M | -257M | -141M | -191M |
| Operating Margin | -47.0% | -47.0% | -14.7% | -34.2% | -20.7% | -27.6% |
| ROE | -99.4% | -68.5% | -17.2% | -31.6% | -12.1% | -2.9% |
| Shares Outstanding | 93M | 93M | 90M | 83M | 81M | 78M |
MYRIAD GENETICS INC passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 252.7x vs a median of 24.1x. The company's 5-year average gross margin is 71.5%. At current prices, the estimated annualized return to fair value is -36.4%.
MYRIAD GENETICS INC (MYGN) has a 5-year average return on invested capital (ROIC) of -24.3%. This is below average and may indicate limited pricing power.
MYRIAD GENETICS INC (MYGN) has a market capitalization of $455M. It is classified as a small-cap stock.
MYRIAD GENETICS INC (MYGN) does not currently pay a regular dividend.
MYRIAD GENETICS INC (MYGN) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
MYRIAD GENETICS INC (MYGN) reported annual revenue of $825 million in its most recent fiscal year, based on SEC EDGAR filings.
MYRIAD GENETICS INC (MYGN) has a net profit margin of -44.4%. The company is currently unprofitable.
MYRIAD GENETICS INC (MYGN) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
MYRIAD GENETICS INC (MYGN) has a debt-to-equity ratio of 0.57. This indicates moderate leverage.
MYRIAD GENETICS INC (MYGN) reported earnings per share (EPS) of $-3.95 in its most recent fiscal year.
MYRIAD GENETICS INC (MYGN) has a return on equity (ROE) of -68.5%. A negative ROE may indicate losses or negative equity.
MYRIAD GENETICS INC (MYGN) has a 5-year average gross margin of 71.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 18 years of financial data for MYRIAD GENETICS INC (MYGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MYRIAD GENETICS INC (MYGN) has a book value per share of $3.97, based on its most recent annual SEC filing.